ID

29240

Beschreibung

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00856986

Link

https://clinicaltrials.gov/show/NCT00856986

Stichworte

  1. 10.03.18 10.03.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

10. März 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Diabetes NCT00856986

Eligibility Diabetes NCT00856986

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00856986
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects diagnosed with type 2 diabetes, insulin naïve and treated with metformin as monotherapy for at least 3 months prior to screening, at a stable dose of at least 1500 mg/day or metformin (at least 1500 mg/day) and a sulfonylurea (less than or equal to half of the maximum approved dose), both at a stable dose for at least 3 months prior to screening. previous short-term insulin treatment in connection with intercurrent illness is allowed at the discretion of the investigator
Beschreibung

Diabetes Mellitus, Non-Insulin-Dependent | Insulin naive | Metformin Dose Stable U/day | Sulfonylurea Dose Stable | Allowed Insulin regime short-term Comorbidity

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0919936
UMLS CUI [3,1]
C0025598
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
UMLS CUI [3,4]
C0456683
UMLS CUI [4,1]
C0038766
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0205360
UMLS CUI [5,1]
C0683607
UMLS CUI [5,2]
C0557978
UMLS CUI [5,3]
C0443303
UMLS CUI [5,4]
C0009488
hba1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy
Beschreibung

Glucohemoglobin measurement | Metformin

Datentyp

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2]
C0025598
hba1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulphonylurea
Beschreibung

Glucohemoglobin measurement | Metformin | Combined Modality Therapy | Sulfonylurea

Datentyp

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0009429
UMLS CUI [4]
C0038766
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with insulin (except for short-term treatment in connection with intercurrent illness at the discretion of the investigator)
Beschreibung

Insulin regime | Exception Therapeutic procedure short-term Comorbidity

Datentyp

boolean

Alias
UMLS CUI [1]
C0557978
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0443303
UMLS CUI [2,4]
C0009488
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 3 months prior to screening
Beschreibung

Hypoglycemic Agents | Exception Inclusion criteria

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020616
UMLS CUI [1,2]
C1705847
UMLS CUI [1,3]
C1512693
recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
Beschreibung

Recurrent severe hypoglycemia | Loss of hypoglycemic warning

Datentyp

boolean

Alias
UMLS CUI [1]
C0342316
UMLS CUI [2]
C0342317
impaired kidney function
Beschreibung

Renal Insufficiency

Datentyp

boolean

Alias
UMLS CUI [1]
C1565489
impaired liver function
Beschreibung

Liver Dysfunction

Datentyp

boolean

Alias
UMLS CUI [1]
C0086565
uncontrolled treated/untreated hypertension
Beschreibung

Uncontrolled hypertension Treated | Uncontrolled hypertension untreated

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1868885
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C1868885
UMLS CUI [2,2]
C0332155
cancer or any clinically significant disease or disorder as judged by the investigator
Beschreibung

Malignant Neoplasms | Disease Clinical Significance

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C2826293
previous participation in the run-in phase of this trial. re-screening is allowed once
Beschreibung

Study Subject Participation Status Run-in Period

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C3274438
history of chronic pancreatitis or idiopathic pancreatitis
Beschreibung

Pancreatitis, Chronic | Idiopathic pancreatitis

Datentyp

boolean

Alias
UMLS CUI [1]
C0149521
UMLS CUI [2]
C0747198

Ähnliche Modelle

Eligibility Diabetes NCT00856986

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00856986
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | Insulin naive | Metformin Dose Stable U/day | Sulfonylurea Dose Stable | Allowed Insulin regime short-term Comorbidity
Item
subjects diagnosed with type 2 diabetes, insulin naïve and treated with metformin as monotherapy for at least 3 months prior to screening, at a stable dose of at least 1500 mg/day or metformin (at least 1500 mg/day) and a sulfonylurea (less than or equal to half of the maximum approved dose), both at a stable dose for at least 3 months prior to screening. previous short-term insulin treatment in connection with intercurrent illness is allowed at the discretion of the investigator
boolean
C0011860 (UMLS CUI [1])
C0021641 (UMLS CUI [2,1])
C0919936 (UMLS CUI [2,2])
C0025598 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
C0456683 (UMLS CUI [3,4])
C0038766 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
C0683607 (UMLS CUI [5,1])
C0557978 (UMLS CUI [5,2])
C0443303 (UMLS CUI [5,3])
C0009488 (UMLS CUI [5,4])
Glucohemoglobin measurement | Metformin
Item
hba1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy
boolean
C0202054 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
Glucohemoglobin measurement | Metformin | Combined Modality Therapy | Sulfonylurea
Item
hba1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulphonylurea
boolean
C0202054 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Insulin regime | Exception Therapeutic procedure short-term Comorbidity
Item
previous treatment with insulin (except for short-term treatment in connection with intercurrent illness at the discretion of the investigator)
boolean
C0557978 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0443303 (UMLS CUI [2,3])
C0009488 (UMLS CUI [2,4])
Hypoglycemic Agents | Exception Inclusion criteria
Item
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 3 months prior to screening
boolean
C0020616 (UMLS CUI [1,1])
C1705847 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
Recurrent severe hypoglycemia | Loss of hypoglycemic warning
Item
recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
boolean
C0342316 (UMLS CUI [1])
C0342317 (UMLS CUI [2])
Renal Insufficiency
Item
impaired kidney function
boolean
C1565489 (UMLS CUI [1])
Liver Dysfunction
Item
impaired liver function
boolean
C0086565 (UMLS CUI [1])
Uncontrolled hypertension Treated | Uncontrolled hypertension untreated
Item
uncontrolled treated/untreated hypertension
boolean
C1868885 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C1868885 (UMLS CUI [2,1])
C0332155 (UMLS CUI [2,2])
Malignant Neoplasms | Disease Clinical Significance
Item
cancer or any clinically significant disease or disorder as judged by the investigator
boolean
C0006826 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
Study Subject Participation Status Run-in Period
Item
previous participation in the run-in phase of this trial. re-screening is allowed once
boolean
C2348568 (UMLS CUI [1,1])
C3274438 (UMLS CUI [1,2])
Pancreatitis, Chronic | Idiopathic pancreatitis
Item
history of chronic pancreatitis or idiopathic pancreatitis
boolean
C0149521 (UMLS CUI [1])
C0747198 (UMLS CUI [2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video